In the Interim...
Episodes
AI @ Berry
04 May 2026
Contributed by Lukas
In the 60th episode of “In the Interim…”, Dr. Scott Berry, Dr. Nick Berry, and Dr. Joe Marion discuss how Berry Consultants uses AI in clinical ...
Drug Development and Sports: The 10-Run Rule and Futility
27 Apr 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Nick Berry investigate how futility in clinical trials and stopping rules in sports il...
ICH-E20, Regulators, and False Choices
20 Apr 2026
Contributed by Lukas
In this episode of "In the Interim…", host Dr. Scott Berry undertakes a detailed, methodical critique of ICH-E20 draft guidance language as applied ...
PANTHER: A Phase 2 International Platform Trial in ARDS
13 Apr 2026
Contributed by Lukas
In this episode of "In the Interim…" Dr. Scott Berry is joined by Professors Victoria Cornelius, Danny McAuley, and Anthony Gordon, for a technical ...
A Visit with Byron Gajewski: KUMC, Innovative Trial Designs, the HOBIT Trial
06 Apr 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry connects with Dr. Byron Gajewski, professor of biostatistics and data science at the Universit...
A Visit with Stephen Senn: Time, Concurrent Controls, and the Bayesian Guidance
30 Mar 2026
Contributed by Lukas
In this episode of "In the Interim...", Dr. Scott Berry hosts Dr. Stephen Senn, award-winning statistician and author, for a discussion on advanced ch...
Making Sense of Hierarchical Composites
23 Mar 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry is joined by statisticians Dr. Amy Crawford, Dr. Cora Allen-Savietta, and Dr. Jessica Overbey ...
The SNAP Trial with Professors Tong and Davis
16 Mar 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry interviews Professors Steven Tong and Josh Davis about the SNAP platform trial for Staphylococ...
Bayesian Borrowing in Phase 3 Trials
09 Mar 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele examine Bayesian borrowing in Phase 3 clinical trials, focusing on statisti...
The Art of Storytelling with Shaun Cassidy
02 Mar 2026
Contributed by Lukas
In Episode 51 of "In the Interim…", Dr. Scott Berry interviews writer, producer, and performer Shaun Cassidy to examine the practical elements of st...
The Fallacy of Ordinal Endpoints
23 Feb 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Lindsay Berry investigate the statistical foundations and clinical implications of ana...
Mr. Berry Goes to Washington
16 Feb 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry marks the podcast’s one-year anniversary, sharing listener metrics, watch data, and regional...
Platform Trial in Orthopaedic Surgery
09 Feb 2026
Contributed by Lukas
Dr. Nathan O’Hara (University of Maryland), Dr. Gerard Slobogean (UC Irvine), and Dr. Sheila Sprague (McMaster University) describe the launch and d...
A Visit with Michael Harhay
02 Feb 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry speaks with Dr. Michael Harhay, Associate Professor at the University of Pennsylvania and Dire...
The FDA Bayesian Guidance
26 Jan 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele deliver a quick reaction to the FDA’s draft guidance on Bayesian statisti...
Path 2 Parkinson's Prevention with Drs. Simuni and Wendelberger
19 Jan 2026
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry is joined by Dr. Tanya Simuni, Arthur C. Nielsen Jr. Professor of Neurology and Director of th...
Statistical Communication
12 Jan 2026
Contributed by Lukas
In this episode of “In the Interim…,” host Dr. Scott Berry examines the challenge of communicating complex statistical concepts to non-statistic...
The Rumor of One Trial for Substantial Evidence
29 Dec 2025
Contributed by Lukas
In this episode of "In the Interim…", host Dr. Scott Berry and frequent co-host Dr. Kert Viele, Senior Statistical Scientist at Berry Consultants, a...
Communication for Scientists: A Discussion with Jenny Devenport
22 Dec 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Jenny Devenport, Global Head of Methods, Collaboration, and Outreach at Roche, joins Dr. Scott Berry for a...
Navigating the Arena: Platform Trials
15 Dec 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry delivers a metaphoric critique of single-question trial infrastructure through the sports aren...
Jumping Hurdles: Interim Analyses for Funding Decisions
08 Dec 2025
Contributed by Lukas
In episode 40 of "In the Interim…", Dr. Scott Berry examines the statistical, operational, and behavioral challenges of using interim analyses as tr...
Discussion with Kaspar Rufibach
01 Dec 2025
Contributed by Lukas
In this episode of "In the Interim...", Dr. Scott Berry interviews Dr. Kaspar Rufibach, Co-Head of Advanced Biostatistical Sciences at Merck. The conv...
Bayesian Statistics in Clinical trials: The Past, Present, and Future
24 Nov 2025
Contributed by Lukas
In this episode of "In the Interim…" guest host Cooper Berry moderates a detailed discussion on the evolution and practice of Bayesian methodology i...
A Visit with Stroke Neurologist Dr. Jeff Saver
17 Nov 2025
Contributed by Lukas
In episode 37 of "In the Interim…", Dr. Jeff Saver, Director of the UCLA Comprehensive Stroke and Vascular Neurology Program, details his shift from...
The Saga of the Lecanemab Adaptive Phase II Trial
10 Nov 2025
Contributed by Lukas
In Episode 36 of "In the Interim…", Dr. Scott Berry and Dr. Don Berry analyze the Phase II trial of Lecanemab (BAN2401) in Alzheimer’s disease, fo...
Teaching Statistics and Data Science through Sports with Dr. Jim Albert
03 Nov 2025
Contributed by Lukas
On this episode of “In the Interim…”, which is co-sponsored by the Journal of Statistics and Data Science Education, Dr. Scott Berry talks with ...
Digital Googols
27 Oct 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry examines the concept of “digital twins” in clinical trials. He details how simulation of c...
A Visit with Andrew Thomson
20 Oct 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry interviews Dr. Andrew Thomson, owner and lead consultant of Regnitio. Thomson discusses his ac...
Moving Clinical Trial Goalposts
13 Oct 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele analyze how regulatory, editorial, and science community standards often im...
The Not So Promising Zone Design
29 Sep 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry examines the mathematical foundations and efficiency claims of the promising zone design for a...
A Visit with Dr. Janet Wittes
22 Sep 2025
Contributed by Lukas
Episode 30 of “In the Interim…” features Dr. Janet Wittes, Fellow of the American Statistical Association, past president of the Society of Clin...
Bayesian Clinical Trials with Frank Harrell
15 Sep 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry chats with Frank Harrell, a professor of Biostatistics at Vanderbilt University and W.J. Dixon...
A Visit with Dr. Derek Angus
08 Sep 2025
Contributed by Lukas
In this episode of “In the Interim…”, Dr. Scott Berry interviews Dr. Derek Angus, Distinguished Professor and Chair of Critical Care Medicine at...
The Mystery of Clinical Trial Simulation
01 Sep 2025
Contributed by Lukas
Dr. Scott Berry hosts this episode of "In the Interim…", opening with statistical analysis of elite athletes before focusing on the misunderstood ro...
Discussions on the ICH E20 Draft Guidance
25 Aug 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele review the ICH E20 draft guidance on adaptive clinical trial designs, offer...
A Discussion with Michael Proschan on Response-Adaptive Randomization
18 Aug 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry and NIH’s Dr. Michael Proschan conduct a detailed discussion from opposing viewpoints on res...
STEP Statistical Modeling
11 Aug 2025
Contributed by Lukas
In this episode of "In the Interim…", Dr. Scott Berry, Dr. Elizabeth Lorenzi, and Dr. Amy Crawford discuss the STEP platform trial’s statistical m...
Bayesian Approach in Clinical Trials
04 Aug 2025
Contributed by Lukas
This episode of "In the Interim…" features Dr. Scott Berry, Dr. Kert Viele, and Dr. Melanie Quintana of Berry Consultants dissecting the technical a...
The Time Machine
28 Jul 2025
Contributed by Lukas
Dr. Scott Berry and Dr. Kert Viele discuss the origins and implementation of the “time machine” modeling approach, beginning with sports analytics...
The Legend of I-SPY 2 - Part B
21 Jul 2025
Contributed by Lukas
In this episode, Dr. Don Berry and Dr. Scott Berry provide an in-depth account of I-SPY 2, focusing on the trial’s use of the “time machine” met...
The Legend of I-SPY 2 - Part A
14 Jul 2025
Contributed by Lukas
In Episode 20 of Berry’s "In the Interim..." Podcast, The Legend of I-SPY 2 - Part A, Dr. Don Berry and Dr. Scott Berry discuss the origins and desi...
The STEP Platform with Dr. Eva Mistry and Dr. Jordan Elm
07 Jul 2025
Contributed by Lukas
This episode of "In the Interim..." features an in-depth discussion of the StrokeNet Thrombectomy Endovascular Platform (STEP), a multi-domain, multi-...
A Statistician reads JAMA
30 Jun 2025
Contributed by Lukas
Dr. Scott Berry applies a statistician’s review of a random trial result published in JAMA – the FAIR-HF2 clinical trial. Interrogating the freq...
Seamless 2/3 Trial Designs
23 Jun 2025
Contributed by Lukas
Scott Berry convenes co-authors Kert Viele, Joe Marion, and Lindsay Berry to discuss the statistical and developmental nuances of inferentially seamle...
Spending Alpha
09 Jun 2025
Contributed by Lukas
In this solo episode of "In the Interim...", Scott Berry, President and Senior Statistical Scientist at Berry Consultants, addresses deep-rooted confu...
Prof Craig Ritchie: Looking Back at EPAD, moving forward in Alzheimer's Disease
02 Jun 2025
Contributed by Lukas
Scott Berry, Founder of Berry Consultants, interviews Professor Craig Ritchie—specialist in brain health and neurodegenerative diseases, Chief Inves...
Drug Developers' Lessons from Sports: Regression-to-the-Mean
26 May 2025
Contributed by Lukas
In this engaging episode of "In the Interim...", host Dr. Scott Berry is joined by Dr. Nick Berry to explore the intriguing statistical parallels betw...
DSMBs in Adaptive Trials with Roger Lewis
19 May 2025
Contributed by Lukas
In this episode of "In the Interim…", host Dr. Scott Berry is true to the name of the podcast, as he discusses the unblinded world of adaptive clini...
Platform Trial in Psychiatry with Dr. Husseini Manji
12 May 2025
Contributed by Lukas
In the latest episode of "In the Interim…", Dr. Scott Berry and Dr. Mike Krams sit down with Dr. Husseini Manji, to explore the potential of platfor...
Implementing Adaptive Trials
05 May 2025
Contributed by Lukas
In Episode 11 of "In the Interim…", we discuss the nuances of implementing adaptive clinical trials with Dr. Anna McGlothlin and Dr. Michelle Detry ...
Revisiting Seamless 2/3 Trial for GLP-1 Agonist
28 Apr 2025
Contributed by Lukas
In this episode of "In the Interim..." we revisit the ground-breaking seamless phase 2/3 clinical trial for the GLP-1 agonist, dulaglutide—better kn...
I-SPY 2 to GBM AGILE and Beyond
21 Apr 2025
Contributed by Lukas
In this episode of "In the Interim...," we sit down with Dr. Meredith Buxton to explore the evolution of platform trials from I-SPY 2 to GBM AGILE and...
External Data in Clinical Trials
14 Apr 2025
Contributed by Lukas
In this episode of "In the Interim...," Scott Berry and Kert Viele navigate the nuanced debate surrounding the integration of external data in clinica...
Remembering Jimmie Savage
07 Apr 2025
Contributed by Lukas
In this episode of "In the Interim," Don Berry shares the life and work of Jimmie Savage, his advisor and a legendary figure in Bayesian statistics. H...
The Art and Slog of Innovating
31 Mar 2025
Contributed by Lukas
In this compelling episode of "In the Interim," Dr. Mike Krams, a seasoned expert in clinical trials and drug development, joins us to discuss the art...
Religion, Politics, and Ordinal Outcomes
24 Mar 2025
Contributed by Lukas
In this episode of "In the Interim," Dr. Scott Berry discusses the vital topic of ordinal outcomes in clinical trials—a subject as controversial as ...
HEALEY ALS Platform Trial with Dr. Merit Cudkowicz and Dr. Melanie Quintana
17 Mar 2025
Contributed by Lukas
In this episode of the podcast, we sit down with Dr. Merit Cudkowicz and Dr. Melanie Quintana to discuss the inception and execution of the Healy ALS ...
FACTS 7.1 Release with Tom Parke
10 Mar 2025
Contributed by Lukas
In this episode of "In the Interim," Berry's Director of Software, Tom Parke, takes us into the fascinating realm of clinical trial simulation. With T...
When should you use adaptive design clinical trials?
03 Mar 2025
Contributed by Lukas
In this episode of "In the Interim," we consider the nuances of adaptive design clinical trials with distinguished guests Dr. Scott Berry and Dr. Kert...
The Story of Berry Consultants
18 Feb 2025
Contributed by Lukas
In the inaugural episode of Berry's "In the Interim...," we sit down with the founders of Berry Consultants, Dr. Don Berry and Dr. Scott Berry. Celebr...